Spondyloarthritis & psoriatic arthritis
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Authors' conclusion
At 3 years, there was generally comparable persistence after ustekinumab or TNFi treatment, but AE rates were lower with ustekinumab.
Study context
- Population
- Patients with PsA prescribed first-line to third-line ustekinumab or a tumour necrosis factor inhibitor (TNFi) (mean age 49.8 years, 44.7% males)
- Participants
- 895 patients
- Exposure
- Ustekinumab vs TNFi in PsA
- Outcome
- Persistence (still on initial treatment) and effectiveness (clinical Disease Activity for PSA (cDAPSA) low disease activity (LDA)/remission, MDA/VLDA)
- Follow-up
- 3 years
Methodological detailsreal-world, propensity-score adjusted, Persistence and effectiveness assessed every 6 months; safety data collected over 3 years
- Real-world
- Propensity-score adjusted
- Persistence and effectiveness assessed every 6 months; safety data collected over 3 years
Main finding
Persistence on initial treatment
Propensity scores (PS)-adjusted HR for stopping/switching
0.87
95% CI 0.68–1.11
By group
Ustekinumabvs TNFi
PS-adjusted HR for stopping/switching 0.87 (95% CI 0.68–1.11)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Ustekinumab | TNFi | PS-adjusted OR (95% CI) | |
|---|---|---|---|---|
| cDAPSA LDA · 3 years | 58.6% | 69.8% | 0.89 (0.63–1.26) | |
| cDAPSA remission · 3 years | 31.4% | 45.0% | 0.72 (0.50–1.05) | |
| 0.512PS-adjusted OR (log scale) |
MDA · 3 years
VLDA · 3 years
MDA · 3 years
- Overlapping PS-adjusted ORs
VLDA · 3 years
- Overlapping PS-adjusted ORs
Original publication
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis. Published 13 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →